"Tetrahydronaphthalenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Partially saturated 1,2,3,4-tetrahydronaphthalene compounds.
| Descriptor ID |
D013764
|
| MeSH Number(s) |
D02.455.426.559.847.638.960 D04.615.638.960
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydronaphthalenes".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydronaphthalenes".
This graph shows the total number of publications written about "Tetrahydronaphthalenes" by people in this website by year, and whether "Tetrahydronaphthalenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 5 | 0 | 5 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 1 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrahydronaphthalenes" by people in Profiles.
-
Nirogacestat, a ?-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 09; 388(10):898-912.
-
Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
-
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 04 20; 39(12):1360-1370.
-
Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatol Ther. 2017 Sep; 30(5).
-
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clin Cancer Res. 2017 Jul 15; 23(14):3552-3556.
-
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.
-
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer. 2015 Nov 15; 121(22):4088-96.
-
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin. 2015 Oct; 33(4):715-29.
-
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7.
-
Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015 Jun; 16(6):678-90.